Thursday, January 09, 2003 2:18:02 PM
IBCI's Partner, Nova BioGenetics, Fills Two Key Positions for Marketing IBCI's Products: National Sales Manager and Technical Marketing Manager
Wednesday January 8, 9:01 am ET
Effective Start Date: February 1, 2003
ATLANTA, Jan. 8 /PRNewswire-FirstCall/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL - News) is pleased to announce that Nova BioGenetics, IBCI's master distribution partner, has filled two key positions for marketing IBCI's products. Ms. Deirdre Baker stated, "After months of reorganization, we are pleased our partner is building a team of highly qualified personnel increasing Nova's ability to provide the right people to market IBCI's products. Both professionals have microbiology degrees and combined experience of over 35 years in the biocide industry and they have worked with the IBCI/BioShield technology for over two years. With their experience, they bring a nationwide network of sales and marketing representatives for the products and a significant number of key account contacts within the antimicrobial industry. Moreover, they bring to the company additional technologies including a multitude of other products to be marketed under the IBCI/Nova joint venture." The expansion of our partner's quality team brings an entirely new dimension to the sale of IBCI products, which has not previously been in place and opens new markets for both IBCI and Nova.
About International BioChemical Industries, Inc.:
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods. To date BioShield has received four US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water. Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling Deirdre Baker at 1-770-925-3653.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
The best weapon against "fear" is "facts"!!
Wednesday January 8, 9:01 am ET
Effective Start Date: February 1, 2003
ATLANTA, Jan. 8 /PRNewswire-FirstCall/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL - News) is pleased to announce that Nova BioGenetics, IBCI's master distribution partner, has filled two key positions for marketing IBCI's products. Ms. Deirdre Baker stated, "After months of reorganization, we are pleased our partner is building a team of highly qualified personnel increasing Nova's ability to provide the right people to market IBCI's products. Both professionals have microbiology degrees and combined experience of over 35 years in the biocide industry and they have worked with the IBCI/BioShield technology for over two years. With their experience, they bring a nationwide network of sales and marketing representatives for the products and a significant number of key account contacts within the antimicrobial industry. Moreover, they bring to the company additional technologies including a multitude of other products to be marketed under the IBCI/Nova joint venture." The expansion of our partner's quality team brings an entirely new dimension to the sale of IBCI products, which has not previously been in place and opens new markets for both IBCI and Nova.
About International BioChemical Industries, Inc.:
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods. To date BioShield has received four US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water. Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling Deirdre Baker at 1-770-925-3653.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
The best weapon against "fear" is "facts"!!
The best weapon against "fear" is "facts"!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
